1. Home
  2. SUPN vs HCM Comparison

SUPN vs HCM Comparison

Compare SUPN & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$43.53

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo HUTCHMED (China) Limited

HCM

HUTCHMED (China) Limited

N/A

Current Price

$14.09

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SUPN
HCM
Founded
2005
2000
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.3B
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
SUPN
HCM
Price
$43.53
$14.09
Analyst Decision
Strong Buy
Sell
Analyst Count
5
1
Target Price
$61.60
$13.75
AVG Volume (30 Days)
581.4K
71.2K
Earning Date
05-05-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$392,755,000.00
N/A
Revenue This Year
$22.70
$20.60
Revenue Next Year
$19.14
$15.62
P/E Ratio
N/A
$5.49
Revenue Growth
N/A
N/A
52 Week Low
$42.45
$9.77
52 Week High
$59.68
$17.79

Technical Indicators

Market Signals
Indicator
SUPN
HCM
Relative Strength Index (RSI) 41.02 74.18
Support Level $44.09 $12.99
Resistance Level $52.33 $14.80
Average True Range (ATR) 1.30 0.29
MACD -0.29 0.04
Stochastic Oscillator 19.63 95.27

Price Performance

Historical Comparison
SUPN
HCM

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

About HCM HUTCHMED (China) Limited

HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.

Share on Social Networks: